Heidelberg Pharma AG (FSE: HPHA) today announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.65% to 99.99%) during the virtual Annual General Meeting today.
This includes the following agenda items: Resolution on the formal approval of the actions of the members of the Executive Management Board and the Supervisory Board for the fiscal year 2019
Resolution on the appointment of the auditor of the annual financial statements and the consolidated financial statements for the 2019/2020 fiscal year
Resolution to revoke the existing Authorized Capital 2018/I and create new Authorized Capital 2020/I as well as to amend the Articles of Association accordingly
Resolution on the authorization of the Executive Management Board to issue convertible bonds or bonds with warrants, to raise contingent capital for this purpose (Contingent Capital 2020/I) and to amend the Articles of Association
Resolution on the election of Supervisory Board members
Resolution to approve the signing of a profit and loss transfer agreement with Heidelberg Pharma Research GmbH
Resolution on amendments to the Articles of Association regarding the conditions of attendance, the Supervisory Board being quorate and the position of Chairman of the Annual General Meeting.
The following members were re-elected to the Supervisory Board of the company: Dr. Birgit Kudlek and Dr. Georg F. Baur as well as Prof. Dr. Christof Hettich, Dr. Friedrich von Bohlen und Halbach and Dr. Mathias Hothum as representatives of the main shareholder dievini Hopp Biotech holding GmbH & Co. KG.
At the Annual General Meeting 2020, 81.48% of the current share capital were represented.
Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: 'We are pleased that our own projects have developed according to plan despite the more difficult situation caused by the corona virus crisis in the first half of the financial year 2020. The preclinical development program for our first ATAC candidate HDP-101 is now nearing completion and we are confident that we will be able to submit the application to the authorities to conduct a clinical trial in the second half of 2020. Thanks to the successful capital increase and the renewed financial commitment of our main shareholder dievini, not only is the clinical development work with HDP-101 secured until mid-2021, but we can also nominate the next development candidates from our portfolio and advance the preclinical work. On behalf of the Management Board, I would like to thank the shareholders of Heidelberg Pharma AG for their trust in our company and their long-standing support.'
Heidelberg Pharma made use of the option provided by the German legislature in view of the coronavirus pandemic to conduct ordinary annual general meetings in 2020 without the physical presence of shareholders or their proxies. Via a password-protected web service, registered shareholders can, among other things, follow the entire Annual General Meeting live via video and audio, exercise their voting rights and submit questions.
Please find more information about the Annual General Meeting including the voting results here: http://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting.
Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.
Contact:
Tel: +49 89 41 31 38-29
Email: investors [at]hdpharma.com
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
HEIDELBERG PHARMA AG 
